Research has shown that ganglioside GD2 is a specific and sensitive tumour biomarker that can distinguish between high and low risk forms of NB, showing promising qualities for a diagnostic and prognostic NB biomarker.321 Balis et al. found that GD2 concentrations were significantly higher in patients with MYCN amplified tumours. The gene discussed is MYCN; the disease is neuroblastoma.